logo-loader
QinetiQ

QinetiQ share price slump brings stock into Goldman's price range

At last night's close, it was still a (marginal) sell for Goldman's, but the stock has wilted again today

Fighter jet
The share price has been shot down this week

Defence technology outfit QinetiQ Group PLC (LON:QQ.) might just have fallen into buying territory for Goldman Sachs.

The stock fell 9.5% yesterday to 248p following a bleak first quarter trading update, taking it below Goldman’s 12-month price target of 253p (down from 255p previously).

“Still a sell”, was the investment bank’s verdict in a research note issued this morning, but that was before the shares tanked further, shedding another 9.8% today at 242.1p.

READ QinetiQ shares tank as new contracts slow in the first quarter

The bank continues to expect pressure on free cash flow from less positive working capital and higher capital expenditure in the coming years.

It has updated its estimate to reflect a better revenue contribution from the newly acquired QTS business, which is now expected to provider a £25mln tailwind for the full year vs. £20mln previously; slightly slower organic revenue growth in Global Products in fiscal 2018 (FY18E in broker-speak), which is now projected at 1.1% vs. 3.7% previously; and a higher effective tax rate (13% vs. 10.6% previously).

Its FY18E earnings per share estimate has been trimmed by 3% to 16.45p from 17.05p.

Quick facts: QinetiQ

Price: £2.99

Market: LSE
Market Cap: £1.7 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

21 hours, 49 minutes ago

2 min read